We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Optimal treatment strategies for severe aplasticanaemia remain to be determined.
2
Then they were given the devastating diagnosis of aplasticanaemia.
3
We present here a patient treated for aplasticanaemia, who developed fungal arthritis of the hip and systemic candidaemia.
4
Aims: To review 10 years of local experience in treating severe aplasticanaemia with BMT and immunosuppressive therapy with emphasis on long-term outcomes.
5
These results suggest that while rIL-1 alpha can be safely administered, no significant haematologic improvement was observed in patients with severe aplasticanaemia.
6
In long-term use it carries a one in 30,000 risk of a serious side effect - the bone marrow disorder aplasticanaemia.